Pfizer Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration.
Pfizer Analysts
SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer.BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target.